Advanced Search

 

Study ID Status Title Patient Level Data
SKF104864/722 Completed A Phase I Study of Oral Topotecan in Subjects with Cancer and Impaired Renal Function
SLGA4004 Completed A Randomized, Double-blind, Double-Dummy, Comparative Clinical Trial of 12-Week Courses of Salmeterol Xinafoate Versus Ipratropium Bromide Versus Placebo (PRN Ventolin) in Subjects With Chronic Obstructive Pulmonary Disease Study Listed on ClinicalStudyDataRequest.com
SLGA4005 Completed A Randomized, Double-Blind, Double-Dummy, Comparative Clinical Trial of 12-Week Courses of Salmeterol Xinafoate Versus Ipratropium Bromide Versus Placebo (PRN Ventolin®) in Subjects With Chronic Obstructive Pulmonary Disease Study Listed on ClinicalStudyDataRequest.com
SLGA5011 Completed SMART: A Double-Blind, Randomized, Placebo-Controlled Surveillance Study of Asthma Event Outcomes in Subjects Receiving Either Usual Pharmacotherapy of Asthma or Usual Pharmacotherapy Plus Salmeterol 42mcg Twice Daily Study Listed on ClinicalStudyDataRequest.com
SLGB1006 Completed A Randomised, Double-Blind, Placebo-Controlled, Cross-Over Study to Compare the Systemic Pharmacodynamic Effects and Pharmacokinetics of Salmeterol Delivered by the Non-CFC Propellant (HFA-134a; GR106642X) and the CFCPropellant (Propellant 11/12) Metered Dose Inhalers in Healthy Subjects Study Listed on ClinicalStudyDataRequest.com
SMO30006 Completed A Multi-Centre, Randomised, Double-Blind, 12-Week, Parallel-Group Study to Compare Salmeterol Xinafoate 50mcg BD Delivered Either via a HFA Metered-Dose Inhaler or via a CFC Metered-Dose Inhaler, in the Treatment of Adults, Aged 12 years and Over, With Asthma Study Listed on ClinicalStudyDataRequest.com
SMO30007 Completed A Multi-Centre, Randomised, Double-Blind, 12-Week, Parallel-Group Study to Compare Salmeterol Xinafoate 50mcg bd Delivered Either via a HFA Metered-Dose Inhaler or via a CFC Metered-Dose Inhaler, in the Treatment of Children Aged 4-11 Years With Asthma Study Listed on ClinicalStudyDataRequest.com
SMS20011 Completed A Five-Week, Randomized, Double-Blind, Double-Dummy, Two-Period, Four-Treatment Crossover, Placebo-Controlled, Balanced, Incomplete Block Design, Multi-Center Study of Salmeterol Inhalation Aerosol 25mcg BID, 25mcg TID, 50mcg BID and Placebo Administered via a Holding Chamber with Facemask in Subjects with Asthma Aged 6 to 23 Months Study Listed on ClinicalStudyDataRequest.com
SMS30076 Completed A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Clinical Trial of 4 Weeks Treatment With SEREVENT Inhalation Aerosol, 25mcg BID, 50mcg BID, and Placebo Administered via a Valved Holding Chamber With Facemask in Subjects With Asthma Aged 24 to 47 Months Study Listed on ClinicalStudyDataRequest.com
SMS30077 Completed Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Center Clinical Trial of Four Weeks Treatment with SEREVENT™ Inhalation Aerosol, 25mcg BID, 50mcg BID and Placebo Administered Via a Valved-Holding Chamber with Facemask in Subjects with Symptoms of Asthma or Reactive Airways Disease Age 6 to 23 months Study Listed on ClinicalStudyDataRequest.com
SMS40314 Completed A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, 8-Week Comparison of Salmeterol Xinafoate Versus Ipratropium Bromide Versus Salmeterol Xinafoate Plus Ipratropium Bromide Versus Placebo in Subjects With Chronic Obstructive Pulmonary Disease Study Listed on ClinicalStudyDataRequest.com
SMS40315 Completed A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel Group, 8-Week Comparison of Salmeterol Xinafoate Versus Ipratropium Bromide Versus Salmeterol Xinafoate Plus Ipratropium Bromide Versus Placebo in Subjects With Chronic Obstructive Pulmonary Disease Study Listed on ClinicalStudyDataRequest.com
SMS40320 Completed A Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of Salmeterol Xinafoate Inhalation Aerosol Versus Ipratropium Bromide and Albuterol Sulfate Inhalation Aerosol in Subjects With Chronic Obstructive Pulmonary Disease Study Listed on ClinicalStudyDataRequest.com
SMS40321 Completed A Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of Salmeterol Xinafoate Inhalation Aerosol Versus Ipratropium Bromide and Albuterol Sulfate Inhalation Aerosol in Subjects With Chronic Obstructive Pulmonary Disease Study Listed on ClinicalStudyDataRequest.com
SMS40329 Completed A Randomised, Single-Blind, Parallel-Group, 28-Day, Pilot Study to Compare the Addition of Inhaled Salmeterol 50µg bid (via the DISKHALER™ Inhaler) or Tulobuterol-Patch 2mg qd Nocte in Adult Asthmatic Subjects who are Symptomatic on Inhaled Corticosteroids Alone Study Listed on ClinicalStudyDataRequest.com
SMS40330 Completed A Randomized, Multi-Center, Cross Over Comparison of Salmeterol Xinafoate Inhalation Powder (50mcg BID) via the DISKUS ™ and Salmeterol Xinafoate Inhalation Aerosol (42mcg BID) via the Metered Dose Inhaler on Measures of Device Preference in Subjects with COPD Study Listed on ClinicalStudyDataRequest.com
SMS40332 Completed A randomised, open-label, parallel group 28-day pilot study to compare the addition of inhaled salmeterol 50mcg b.i.d. (via the DISKHALER inhaler) or tulobuterol patch 2mg once daily nocte in adult asthmatic subjects symptomatic on treatment with inhaled corticosteroids. Study Listed on ClinicalStudyDataRequest.com
SRT-501-006 Completed A placebo-controlled pharmacokinetic and safety study of twice daily SRT501 in type 2 diabetic human male subjects Study Listed on ClinicalStudyDataRequest.com
SUM10948 Completed An open, randomised, single-dose, three-way crossover, pilot study investigating the relative bioavailability of two newly formulated fast disintegrating sumatriptan 50mg tablets versus the currently marketed sumatriptan 50mg tablets in healthy volunteers Study Listed on ClinicalStudyDataRequest.com
SUM10950 Completed An open, randomised, four-period crossover study to demonstrate the bioequivalence of fast disintegrating sumatriptan tablets (50 and 100 mg tablets) compared with the currently marketed sumatriptan tablets (50 and 100 mg IMITREX† /IMIGRAN† tablets), in healthy male and female volunteers Study Listed on ClinicalStudyDataRequest.com
SUM10954 Completed An open, randomised, three-period crossover study to demonstrate the bioequivalence of fast disintegrating sumatriptan 100mg tablet compared to the currently marketed sumatriptan 100mg tablet administered immediately after food and the fast disintegrating tablet administered in the fasted state to healthy male and female subjects Study Listed on ClinicalStudyDataRequest.com
SUM10961 Completed An open, randomised, two-period crossover study to demonstrate the bioequivalence of fast disintegrating sumatriptan 100 mg tablet dissolved in water compared to the currently marketed sumatriptan 100 mg tablet administered in the fasted state to healthy male and female subjects Study Listed on ClinicalStudyDataRequest.com
SUM20033 Completed A Randomised, Double-Blind, Placebo-Controlled, In-Clinic Pilot Study To Investigate The Efficacy And Tolerability Of 100mg Sumatriptan Administered As A Film-Coated, Fast Disintegrating Tablet Study Listed on ClinicalStudyDataRequest.com
SUM30045 Completed A Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate Two Dose Levels (5mg And 20mg) Of Sumatriptan Nasal Spray In The Acute Treatment Of A Single Migraine Attack In Adolescent Migraineurs (12-17 Years Of Age) Study Listed on ClinicalStudyDataRequest.com
SUM30046 Completed A randomised, double-blind, single-attack, placebo-controlled, parallel group evaluation of the efficacy and tolerability of sumatriptan Fast Disintegrating Tablets (FDT) 50 mg and 100 mg versus placebo during the mild pain phase of a migraine attack. Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.